Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’

The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times.

Here’s Why Atossa Genetics (ATOS) Stock Skyrocketed Today

Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Atossa Genetics …

Maxim Stays Bullish on Atossa (ATOS) Stock Following Preliminary Phase 1 Results

In a research note issued Thursday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Atossa (ATOS), with a $10 price target, …

Why Did Atossa Genetics Inc (ATOS) Shares Shoot the Lights Out Today?

Atossa Genetics (NASDAQ:ATOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% upturn. …

Atossa Genetics (ATOS) Stock Plunges After Reverse Stock Split Announced

A wave of reverse stock splits appears almost inevitable, as battered stocks try to maintain their stock listing and win over investors who …

Atossa Genetics Inc (ATOS) Is Ready to Explore the Potential of Endoxifen in Treating Men’s Breast Health; Shares Jump 9%

Atossa Genetics Inc (NASDAQ:ATOS) investors are upbeat today upon news that this biotech player’s breast health program is getting an expansion. Specifically, the …

Here’s Why Atossa Genetics Inc (ATOS) Stock Tumbles 25% Today

Shares of tiny-cap biopharma Atossa Genetics Inc (NASDAQ:ATOS) are falling nearly 25% on Friday, after the company announced 2017 financial results yesterday afternoon. …

Atossa Genetics Inc Could Have an Asset That Kills Breast Cancer Cells Faster and Improves Clinical Outcomes; Jason Kolbert Weighs In

Following Phase 1 trial data for Atossa’s oral endoxifen, Maxim’s Jason Kolbert spotlights 208% in return potential for the stock.

Biotech Movers: Atossa Genetics Inc Raises on Back of Positive Early Clinical Data in Breast Cancer

Atossa Genetics is among the biotech stock movers in after-hours trading Thursday.

Atossa Genetics Inc: Could Accelerated Timelines to Approvals Lie Ahead? Jason Kolbert Weighs In

Maxim’s Jason Kolbert sheds light ahead of tomorrow’s Phase 1 oral endoxifen findings.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts